在2026年2月3日,三名探戈治疗内幕人士出售了59 000多股股票,共计约727 000美元。 Three Tango Therapeutics insiders sold over 59,000 shares on Feb. 3, 2026, totaling about $727,000.

2月3日, 2026年2月3日, 三位探戈治疗内幕人士Barbara Weber、Adam Crystal和CFO Daniella Beckman共出售59 288股, 每股12.26美元,共计约726 870美元。 On February 3, 2026, three Tango Therapeutics insiders—Barbara Weber, Adam Crystal, and CFO Daniella Beckman—sold a combined 59,288 shares at $12.26 per share, totaling about $726,870. 销售量分别减少了1.84%、8.97%和5.3%。 The sales reduced their stakes by 1.84%, 8.97%, and 5.3% respectively. 该公司的股票于2月4日以12.32美元关闭,减少了0.23美元,数量低于平均水平。 The company’s stock closed at $12.32 on February 4, down $0.23, with below-average volume. 尽管出现负净差和预计年亏损,但探戈治疗研究所报告,2025年11月Q4收入强劲,超过估计数。 Despite a negative net margin and projected annual loss, Tango Therapeutics reported strong Q4 earnings in November 2025, surpassing estimates. 该股票具有“机动购买”共识评级和13.60美元目标价格。 The stock has a “Moderate Buy” consensus rating and a $13.60 target price.